Pacira BioSciences
PCRX
301 hedge funds and large institutions have $3.79B invested in Pacira BioSciences in 2022 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 110 increasing their positions, 95 reducing their positions, and 26 closing their positions.
115% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 26
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
24% more capital invested
Capital invested by funds: $3.05B → $3.79B (+$741M)
16% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 95
9% more funds holding
Funds holding: 276 → 301 (+25)
2.9% less ownership
Funds ownership: 113.63% → 110.73% (-2.9%)
90% less call options, than puts
Call options by funds: $2.75M | Put options by funds: $26.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$40.4M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$22.7M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$20.3M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$20.3M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$19.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
-$80.4M |
| 2 |
AC
Armistice Capital
New York
|
-$52.5M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$45M |
| 4 |
DM
Deerfield Management
New York
|
-$35.9M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$15.7M |
PCRX Hedge Fund Activity: Q1 2022 in Review
301 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q1 2022, worth a combined $3.79B — up 24% from $3.05B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new PCRX positions and 26 closed out — a net gain of 30 holders — while 110 added to existing stakes and 95 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $40.4M. The largest seller was Paulson & Co, cutting an estimated $80.4M.
- 301 institutional investors held Pacira BioSciences (PCRX) as of Q1 2022, up from 276 in Q4 2021.
- Funds reported $3.79B of Pacira BioSciences stock for Q1 2022, up 24% quarter-over-quarter.
- 56 funds opened new Pacira BioSciences positions in Q1 2022 and 26 closed out, a net change of +30 holders.
- The largest Pacira BioSciences buyer in Q1 2022 was Wellington Management Group, an estimated $40.4M added.
- The largest Pacira BioSciences seller in Q1 2022 was Paulson & Co, an estimated $80.4M sold.
Based on aggregated 13F filings for Q1 2022.